Senores Pharmaceuticals Limited has informed the Exchange regarding Media Release-"Senores Pharmaceuticals acquires ANDA for Enalapril Maleate Tablets 2.5mg, 5mg, 10mg and 20mg from Wockhardt"
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Senores Pharmaceuticals, through its US subsidiary Senores Pharmaceuticals Inc., has signed an agreement to acquire the USFDA-approved ANDA for Enalapril Maleate Tablets (2.5mg, 5mg, 10mg and 20mg) from Wockhardt Limited. Enalapril is used to treat hypertension, heart failure, and asymptomatic left ventricular dysfunction. The US market for Enalapril Tablets is estimated at approximately USD 28.60 million (IQVIA, MAT Dec 2024) to USD 109.24 million (Symphony, MAT Mar 2025), depending on the data source. The acquisition will be funded entirely from the proceeds of the company's recent IPO, as outlined in the Red Herring Prospectus. This adds to Senores' existing portfolio of 61 ANDAs and 22 CMO/CDMO products approved for the US market.
This is a strategic, in-line expansion of Senores' US generics portfolio using IPO funds as promised, adding a cardiovascular drug to its offerings. The market is relatively modest in size, so the immediate revenue impact may be limited, but it strengthens the company's US pipeline and signals disciplined use of IPO capital.